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Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) are diverse
immune systems found in many prokaryotic genomes that target invading foreign DNA
such as bacteriophages and plasmids. There are multiple types of CRISPR with arguably
the most enigmatic being Type IV. During an investigation of CRISPR carriage in clinical,
multi-drug resistant, Klebsiella pneumoniae, a Type IV-A3 CRISPR-Cas system was
detected on plasmids from two K. pneumoniae isolates from Egypt (isolated in 2002–
2003) and a single K. pneumoniae isolate from the United Kingdom (isolated in 2017).
Sequence analysis of all other genomes available in GenBank revealed that this CRISPR-
Cas system was present on 28 other plasmids from various Enterobacteriaceae hosts
and was never found on a bacterial chromosome. This system is exclusively located
on IncHI1B/IncFIB plasmids and is associated with multiple putative transposable
elements. Expression of the cas loci was confirmed in the available clinical isolates by
RT-PCR. In all cases, the CRISPR-Cas system has a single CRISPR array (CRISPR1)
upstream of the cas loci which has several, conserved, spacers which, amongst things,
match regions within conjugal transfer genes of IncFIIK/IncFIB(K) plasmids. Our results
reveal a Type IV-A3 CRISPR-Cas system exclusively located on IncHI1B/IncFIB plasmids
in Enterobacteriaceae that is likely to be able to target IncFIIK/IncFIB(K) plasmids
presumably facilitating intracellular, inter-plasmid competition.
Keywords: Type IV, IncFIIK, IncFIB(K), inter-plasmid competition, mobile genetic element
INTRODUCTION
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR-Cas) are widespread,
adaptive, RNA-mediated, immune systems found in the genomes of prokaryotic organisms
(bacteria and archaea) that target invading foreign DNA such as bacteriophages and conjugative
plasmids (Barrangou et al., 2007; Marraffini and Sontheimer, 2010a). CRISPR functions through
a three-stage process: adaptation involving the acquisition of foreign DNA molecules as spacers,
expression and maturation of the short CRISPR RNAs (crRNAs), and the interference with a
cognate invading foreign DNA molecule (Rath et al., 2015). The classification of CRISPR-Cas
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systems is continuously updated to include newly identified
subtypes. To date, CRISPR-Cas systems are classified into two
classes, six Types (I–VI), and ∼ 33 subtypes (Koonin et al.,
2017; Makarova et al., 2018, 2020). There is ongoing discovery
of multiple, novel class 2 CRISPR-Cas systems (Makarova et al.,
2020). The two classes differ according to the effector module;
class 1 utilizes multi-protein effector Cas complexes, while class
2 utilizes a single-protein effector [Type II contains Cas9; Type V
contains Cas 12a (previously known as Cpf1), Cas12b (previously
known as C2c1), Cas12c (previously known as C2c3), Cas12d
(previously known as CasY), and Cas12e (previously known
as CasX); and Type VI contains Cas13a (previously known
as C2c2), Cas13b, and Cas13c] (Makarova and Koonin, 2015;
Makarova et al., 2015, 2017; Pyzocha and Chen, 2018). CRISPR-
Cas systems are confirmed, or expected, to provide immunity
against viruses and other mobile genetic elements (MGEs),
except for transposon-encoded CRISPR-Cas systems that lack
the interference module and therefore are predicted to perform
functions distinct from adaptive immunity (Makarova et al.,
2020). Most of the CRISPR types target DNA, some types
specifically target RNA such as Type VI, while Type III CRISPR
systems are unique because they exhibit both RNA interference
and DNA interference in vivo to protect their microbial hosts
(Marraffini and Sontheimer, 2008, 2010b; Hale et al., 2009; Deng
et al., 2013; Manica et al., 2013; Goldberg et al., 2014; Tamulaitis
et al., 2014; Zebec et al., 2014; Peng et al., 2015; Samai et al., 2015;
Elmore et al., 2016; Estrella et al., 2016; Kazlauskiene et al., 2016;
Zhang and Ye, 2017; Ozcan et al., 2019; Lin et al., 2020).
Type IV was previously called the Unknown Type (Type
U), due to its rare occurrence and lack of the adaptation
module, until an updated classification in 2015 (Makarova
et al., 2013; Zhang and Ye, 2017). It was then named Type IV
(putative) after its identification in Acidithiobacillus ferrooxidans
presenting a different genetic arrangement of Type U cas genes
(Makarova et al., 2015). In 2017, Type IV classification was
updated, after its identification in Thioalkalivibrio sp. K90mix
(TK90_2699-TK90_2703), to show an associated repeat-spacer
array for a cas loci that have csf4 (dinG), csf5 (cas6-Like), csf1
(cas8-Like), csf2 (cas7), and csf3 (cas5) genetic arrangement,
respectively, and was then assigned as Type IV-A (Koonin
et al., 2017). In 2018, a variant of Type IV that lacks a repeat-
spacer array from Rhodococcus jostii RHA1 (RHA1_ro10069-
RHA1_ro10072), was assigned as Type IV-B (Figure 1; Makarova
et al., 2018). In 2019, the Type IV-C CRISPR-Cas system was
formally classified as a distinct subtype after its identification
in nine contigs; mostly from thermophilic microorganisms
(Makarova et al., 2020). Other papers have also proposed
the classification of Type IV-D, Type IV-E, and subgroups of
Type IV-A(1-4) (Crowley et al., 2019; Pinilla-Redondo et al.,
2019), however, the suggested subgroups did not have a unified
genetic arrangement corresponding for each of the named
Type IV-A(1-4) variants. Type IV CRISPR-Cas systems were
shown to employ crRNA-guided effector complexes (Ozcan
et al., 2019). Type IV is the only type to possesses csf4 (dinG)
in its CRISPR-Cas loci (Dwarakanath et al., 2015; Koonin
et al., 2017), and it was recognized initially as the signature
proteins for Type IV systems, (Makarova and Koonin, 2015;
Crawley et al., 2018) although recently subtype IV-D has been
shown to carry a helicase of the RecD family in place of
the archetypal DinG (Pinilla-Redondo et al., 2019). To date,
Type IV variants (IV-A, IV-B, and IV-C) described above show
different genetic arrangements and orientation of cas loci, and
they all lack the adaptation module. Also, all Type IV CRISPR-
Cas systems are encoded by bacterial plasmids, prophages or
other, uncharacterized integrated elements (Faure et al., 2019b).
Thus, it has been hypothesized that Type IV is similar to an
ancestral innate immune system that gained adaptive ability by
associating with a transposon-like element containing cas1 and
cas2 (Rath et al., 2015).
MATERIALS AND METHODS
Clinical Isolates Sequencing
Three clinical isolates were investigated; Klebsiella pneumoniae-
53 and K. pneumoniae-65 were isolated from Egyptian university
teaching hospitals (2002–2003), and K. pneumoniae-CR5 from
University College London Hospital in the United Kingdom
(2017). The bacterial genomic DNA sequencing was conducted
at MicrobesNG (Birmingham, United Kingdom). Isolates were
sequenced using an Illumina HiSeq 2500 and an Illumina MiSeq
instruments, to boost coverage, with a 2 × 250 bp paired end
sequencing using Nextera XT library prep.
CRISPR-Cas System Identification and
Characterization
DNA sequences were analyzed using CRISPRFinder,
CRISPRCasFinder, CRISPRTarget, and Snapgene (GSL
Biotech) (Grissa et al., 2007; Lundgren et al., 2015;
Couvin et al., 2018; GSL, 2020). The Cas domain analyses
were performed by HHpred (Sensitive protein homology
detection, function, and structure prediction based on
HMM–HMM comparison) at MPI bioinformatics Toolkit1
(Zimmermann et al., 2018). HHpred was performed using
NCBI_Conserved_Domains(CD)_v3.16 and TIGRFAMs_v15.1
databases and Bac_Escherichia_coli_K12_07_Mar_2017
proteome settings. Multi-Locus Sequence Typing, resistance
genes and plasmids were identified using MLST, ResFinder,
and PlasmidFinder, respectively (Carattoli et al., 2014). Spacer
analysis was performed by BLAST and Geneious (Kearse et al.,
2012). A phylogenetic UPGMA-based tree was constructed
for CRISPR arrays and Cas proteins using MEGA X 10.1
(Kumar et al., 2016; Shen et al., 2017). The alignment of the
regions containing protospacers (including 10 bp flanking the
protospacer) associated with CRISPR1 repeats were investigated
to identify putative protospacer adjacent motif (PAM) signature,
as described in Pinilla-Redondo et al. (2019). PAMs were
identified based on compared alignments of nucleotides
immediately preceding each detected protospacer in all or up
to ten unique protospacers of all the investigated sequences.
The leader sequence was identified by sequence alignment.
Direct repeats and PAM conservation were assessed using
1https://toolkit.tuebingen.mpg.de/tools/hhpred
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FIGURE 1 | Schematic representation of Type IV CRISPR-Cas systems and the newly identified variant of Type IV-A. (A) Type U (unknown) as identified in 2013
(Makarova et al., 2013). (B) Type IV (putative) as identified in Acidithiobacillus ferrooxidans in 2015 (Makarova et al., 2015), however, the two associated
repeat-spacer arrays were identified in this study. (C) Type IV-A identified in Thioalkalivibrio sp. K90mix (TK90_2699-TK90_2703) in 2017 (Makarova et al., 2018).
(D) Type IV-B identified in Rhodococcus jostii RHA1 (RHA1_ro10069-RHA1_ro10072) in 2017 (Makarova et al., 2018). (E) Type IV-C identified in Thermoflexia
bacterium D6793_05715-D6793_05700 (Makarova et al., 2020). (F) Type IV-A3 as detected in Enterobacteriaceae isolates and genomes in this study. Arrows in
different colors represent genes; red represents cas6; bright blue represents dinG; light green represents other essential genes of the system; cas8-like/LS, cas7 and
cas5; white represents cas11; blue-yellow pattern represents the direct repeat-spacer loci.
WebLogo, RNA secondary structure was predicted using
RNAfold (Hofacker, 2003; Crooks et al., 2004; Mathews, 2005;
Mojica et al., 2009). The GC skew plots were generated using
the GenSkew online analysis tool2. Presence in other GenBank
sequences was investigated by BLASTn3.
CRISPR-Cas System Expression
The CRISPR-Cas loci expression was tested. RT-PCR was
performed using LightCycler R© RNA Amplification Kit SYBR
Green (Roche Diagnostics Ltd., United Kingdom). The
primers were designed for fully characterized genes (csf2-
fw:AAAATGCGGTCTCAACTTCCG; csf2-rev:TGACGAAGAG
TTCCCCGAATG), (dinG-fw:GAGTCTGCCGGATTGTCGTTA;
dinG-rev:GTACCAGATAGCCCAGCGTTT), and (cas6-fw:AAT
GCGTTTCGGTTGCGTATC; cas6-rev:GAGTACGGCAGCTT
CTCTCC).
2http://genskew.csb.univie.ac.at/
3https://blast.ncbi.nlm.nih.gov/
RESULTS AND DISCUSSION
Identification of Type IV-A3 CRISPR-Cas
in Clinical and GenBank Isolate
Sequences
Type IV-A-3 CRISPR-Cas, based on the gene composition
and genetic architecture of the IV-A variants detected in
K. pneumoniae as described in Pinilla-Redondo et al. (2019),
was detected on a total of thirty-one (three clinical isolates and
twenty eight sequences from GenBank) IncHI1B/IncFIB(Mar)
plasmid sequences within Enterobacteriaceae (Figure 1 and
Supplementary Table S1). The IncH1B/IncFIB plasmids are
large, low copy number, conjugative plasmids with narrow-host-
ranges, which are found in multiple genera of Enterobacteriaceae
(Zhong et al., 2005; Suzuki et al., 2010; Faure et al., 2019a).
An important feature of IncH1B/IncFIB plasmid biology is the
entry exclusion by which the cells that contain an IncF/IncH
plasmid become poor recipients in additional conjugation
rounds (Garcillan-Barcia and de la Cruz, 2008; Ravenhall
et al., 2015); which frees a resident plasmid from competition
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with related plasmids at segregation during bacterial division
but may contribute to limiting plasmid dissemination among
potential hosts.
This Type IV-A3 CRISPR-Cas is characterized by the presence
of a cas loci containing dinG, which is a distinct feature of Type
IV-A CRISPR-Cas system that was shown to be a requirement
for the system functional activity in Pseudomonas aeruginosa
(Crowley et al., 2019; Pinilla-Redondo et al., 2019; Makarova
et al., 2020), a conserved leader sequence and a CRISPR array
in all the detected sequences and they all show homology to
each other. These Type IV-A3 CRISPR-Cas systems were initially
detected by BLAST that confirmed the presence of three genes;
cas7, dinG, and cas6, and further HHpred analysis of other
associated ORFs revealed the presence of two more genes; cas5
and cas8-like.
Association Between Type IV-A3
CRISPR-Cas Sequences and
IncHI1B/IncFIB(Mar) Plasmids
We also identified partial related Type IV-A3 systems
either (cas8-like, cas6, and dinG) or (cas7 and a CRISPR
array) occurring on other IncHI1B/IncFIB(Mar) plasmids
(Supplementary Table S1). Partial and complete Type IV-
A3 system characterization showed occurrence of a range of
different IS elements and retrotransposons (group II introns)
(Supplementary Table S1). The average GC content of this Type
IV-A3 CRISPR-Cas loci (47.7± 0.01%) was found to be closer to
that of the IncHI1B/IncFIB(Mar) plasmids on which they reside
(46.2 ± 0.01%), compared to the chromosomal sequences of the
bacterial host (57± 0.02%), (Table 1).
Characterization of the Type IV-A3
CRISPR-Cas System Found in
Enterobacteriaceae
A single CRISPR array (CRISPR1) was identified upstream of
all cas loci. The repeats have a predicted stem-loop secondary-
structure (Figures 2A,B) and is likely involved in a pre-crRNA
Cas6-mediated process. The alignment of the regions around
and containing the protospacer, particularly the last six positions
preceding the protospacer, associated with CRISPR1 repeats
revealed the conservation of the putative PAM signature (AAG)
adjacent to the end of the protospacers (Figure 2C). A highly
conserved 65 bp leader sequence occurring between the CRISPR-
Cas loci and the CRISPR array was observed in all the sequences
(Figure 2D). The minor variations in the leader sequence only
occurred in two sequences (C in position−63 is A in CP014776.1
Pluralibacter gergoviae, and G in position −41 is A, and C in
position −39 is T in K. pneumoniae-CR5 ST-392). The high
conservation of the leader sequence is unlike that presented in
Pinilla-Redondo et al. (2019). RT-PCR of the confirmed cas loci
(cas7, dinG, and cas6) demonstrated that they are expressed in all
three of the available clinical isolates (Table 2).
We have detected a total of 467 spacers in the 31
CRISPR1 arrays analyzed, out of which 9% (42/467) match to
bacteriophages and 25.5% (119/467) match to plasmid sequences.
The majority of spacer sequences are present in more than
one spacer array and some are present more than once within
the same array (Figure 3). Plasmid targeting spacers appeared
in every example of this Type IV-A3 associated CRISPR array
analyzed. Sequence analysis revealed that spacers correspond
to IncFIIK conjugal transfer genes; traN and traL (Figure 3).
Limited conservation within the order of the spacer arrays
showed that the arrays cluster into two distinct groups which
share geographical associations and suggest persistence within
the plasmid pool in isolates from certain countries over
time (Figure 4).
The CRISPR system described here is always found associated
with IncH1B/IncFIB plasmids in Enterobacteriaceae, has dinG
and cas7 (involved in interference), and cas6, cas5, and cas8-like
(involved in expression and maturation of short crRNAs) (Cass
et al., 2015; Dwarakanath et al., 2015; Koonin and Krupovic,
2015; Lundgren et al., 2015; Crowley et al., 2019; Faure et al.,
2019b). The detection of a csf1/cas8-like in the Type IV-A-
variant described here updates the initial (Newire et al., 2019)
and subsequent (Kamruzzaman and Iredell, 2019) reports of
this system. Additionally, our results agree with other reports
suggesting a need for Type IV-A variant classification (Crowley
et al., 2019; Pinilla-Redondo et al., 2019).
Notably, some of the previously described Type IV systems do
not possess a dinG or cas8-like (e.g., Type IV-C); however, cas7
genes are consistently found in all the previously and presently
described Type IV sequences. Also, Cas7 is the most conserved
protein among members of the Type IV CRISPR family (Pinilla-
Redondo et al., 2019). This highlights the role of cas7 in Type
IV identification.
This Type IV-A3 described here has a variable CRISPR
array and a conserved leader sequence. The conserved leader
sequence occurrence in a wide variety of K. pneumoniae sequence
types may reflect their narrow association with IncH1B/IncFIB
plasmids. Conserved leader sequences in other types (Type I-E)
were shown to increase acquisition efficiency by presumably
stabilizing the Cas1–2-leader-repeat interaction (Kieper et al.,
2019). The order of spacers demonstrated conservation with
some polymorphism, and they cluster into two main groups
(Figure 4) matching DNA from a variety of geographical sources.
Expression of this Type IV-A cas genes suggests immunity to
incoming DNA matching the spacers. Crowley et al. (2019)
posit that interference is mediated, similar to type I and type
III systems, through multi-subunit complexes composed of Csf
proteins and the use of crRNA as a guide to bind complementary
nucleic acid forming R-loops. In this case, it was hypothesized
that DinG is then recruited to these R-loops, where it either
acts directly to destroy the foreign DNA (e.g., a plasmid)
or recruits an endogenous nuclease to mediate RNA-guided
interference (Crowley et al., 2019); however, this needs to be
tested. Also, we note that the adaptation module is missing,
thus adding new spacers will require cas1 and cas2 from other
CRISPR-Cas systems. Like other Type IV systems that cannot
function as independent adaptive immune systems (Koonin and
Krupovic, 2015), we suspect that the Type IV-A3 CRISPR-
Cas described here is likely to co-operate with other cas loci,
whenever they exist within the Enterobacteriaceae host genomes,
for spacer acquisition. Those CRISPR-Cas loci could belong to
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TABLE 1 | Comparison of the GC content of the CRISPR, host plasmid and host strain chromosome.
Sequence (strain name, plasmid name, Accession number) Chromosomal
Size (bp)
Chromosomal
GC
Content
(%)
Plasmid
Size (bp)
Plasmid
GC
Content
(%)
New Type
IV-A Size
(bp)
New Type
IV-A GC
Content
(%)
1 K. pneumoniae 234-12, pKpn23412-362, CP011314.1 5,278,254 57 361,964 48 5,671 47
2 K. pneumoniae Kp15, pENVA, HG918041.1 * * 253,984 47 6,093 47
3 E. coli strain Ecol_422, pEC422_1, CP018961.1 4,747,607 51 289,903 46 5,864 48
4 K. pneumoniae 825795-1, unnamed1, CP017986.1 5,373,055 51 244,706 45 5,979 48
5 K. pneumoniae KP_Goe_828304, pKp_Goe_304-1, CP018720.1 5,373,056 58 246,757 45 6,034 48
6 K. pneumoniae Kp_Goe_152021, pKp_Goe_021-1, CP018714.1 5,373,055 58 246,756 45 5,979 48
7 K. pneumoniae Kp_Goe_827026, pKp_Goe_026-1, CP018708.1 5,373,056 57 246,756 45 6,034 48
8 K. pneumoniae Kp_Goe_827024, pKp_Goe_024-1, CP018702.1 5,374,118 57 246,753 45 6,034 48
9 K. pneumoniae Kp_Goe_149832, pKp_Goe_832-1, CP018696.1 5,373,057 57 246,755 45 6,034 48
10 K. pneumoniae MS6671.v1, LN824134.1 5,402,900 57 279,305 47 7,044 47
11 K. pneumoniae, pNDM-MAR, JN420336.1 * * 267,242 47 8,215 46
12 K. pneumoniae A64477, pKP64477b, MF150122.1 * * 205,089 45 6,282 47
13 P. gergoviae FB2, pFB2.1, CP014776.1 5,489,680 59 242,312 45 5,921 48
14 K. pneumoniae KPN528, pKPN528-1, CP020854.1 5,383,018 57 292,471 46 5,676 48
15 K. pneumoniae Kp_Goe_149473, pKp_Goe_473-1, CP018687.1 5,373,056 57 246,757 45 5,979 48
16 K. pneumoniae Kp_Goe_822579, pKp_Goe_579-1, CP018313.1 5,381,436 57 245,975 45 5,979 48
17 K. pneumoniae Kp_Goe_154414, pKp_Goe_414-1, CP018339.1 5,159,815 58 204,862 45 5,738 48
18 K. pneumoniae AR_0068, unitig_1, CP020068.1 5,357,430 57 276,460 47 5,678 48
19 K. pneumoniae 11, pIncHI1B_DHQP1300920, CP016921.1 5,184,828 58 283,369 46 5,678 48
20 K. pneumoniae KP617, KP-plasmid1, CP012754.1 5,416,282 57 273,628 46 5,678 48
21 K. pneumoniae PittNDM01, plasmid1, CP006799.1 5,348,284 58 283,371 46 5,678 48
22 K. pneumoniae SKGH01, unnamed 1, CP015501.1 5,490,611 57 281,190 47 7,036 49
23 K. pneumoniae PMK1, pPMK1-NDM, CP008933.1 5,317,001 57 304,526 47 8,521 46
24 K. pneumoniae KPNIH48, pKPN-edaa, CP026398.1 5,531,975 57 249,238 47 6,032 48
25 K. pneumoniae KPN1481, pKPN1481-1, CP020848.1 5,554,150 58 347,748 47 8,518 48
26 K. pneumoniae KSB2_1B, unnamed1, CP024507.1 5,228,889 58 310,025 47 5,678 48
27 K. pneumoniae KPNIH50, pKPN-bbef, CP026172.1 5,616,605 57 243,967 46 6,042 48
28 K. pneumoniae F44, p44-1, CP025462.1 5,460,465 57 261,706 48 5,434 48
29 K. pneumoniae-53, plasmid1, SGOL01000000 6,501,177 59 45,187 46 5,671 47
30 K. pneumoniae-65, plasmid 1, SGOK01000000 5,850,021 57 45,574 46 5,671 47
31 K. pneumoniae-CR5, plasmid 1, SGOJ01000000 5,871,238 59 125,699 43 6,284 48
A K. pneumoniae K66-45, pK66-45-1, CP020902.1 5,380,605 57 338,512 48 6,078 46
B K. pneumoniae AR_0158, tig00000727, CP021699.1 5,165,071 58 354,705 48 3,177 48
C K. pneumoniae LS356, pKP8-2, CP025638.1 5,409,425 58 153,586 49 3,133 47
D K. oxytoca pKOX3, p1, KY913897.1 * * 239,374 47 1,085 48
Average 5,422,844 57 251,035 46.2 5,875 47.7
STD 286,043 0.0172 69,579 0.012 1,321 0.01
GC content comparison among the newly described Type IV-A CRISPR-Cas loci, the IncHI1B/IncFIB(Mar) plasmid and isolate chromosomal sequences of the host. *The
strain chromosomal sequence was not available on GenBank; only the plasmid sequence was available.
those CRISPR systems that are known to be frequently associated
with an Enterobacteriaceae host, such as Type I-E/I-E∗ or Type
I-F (Aydin et al., 2017). The association between Type IV-A
and cas6e and cas6f (cas6 sequences observed in subtypes I-E
and I-F, respectively) was previously reported in other bacterial
families, suggesting functional links (Pinilla-Redondo et al.,
2019; Taylor et al., 2019). These functional links were inferred
based on the similarities in the leader and the repeat sequences
of Type I-E and Type IV-A3 (Pinilla-Redondo et al., 2019).
Another evidence that supports possible functional co-operation
is the presence of Cas6 that shows 99%+ identity to Type I-E
Cas6 in Enterobacteriaceae in the Type IV-A3 described here.
Furthermore, unlike other Cas proteins associated with Type
IV-A3 described here, Cas6 were highly conserved sequences,
showing no particular association with interrupting IS elements,
which may further support the recruitment of cas6 is form Type
I-E. These possible adaptation functional links appear to be a
feature that can be switched on/off, which requires the presence
of the IncHI1B/IncFIB(Mar) plasmids (that carry this Type IV-A-
variant) inside a bacterial host that has a functional CRISPR-Cas
system in its genome. Although a previous report suggested that
Type IV CRISPR-Cas system-positive plasmids were only found
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FIGURE 2 | Type IV-A3 conserved repeats and the predicted stable stem-loop secondary structure, putative PAM and leader sequence. (A) Type IV-A-variant
conserved repeats. The height of the letters in the sequence logo shows the relative frequency of their recurrence at that position. Wobbles at positions 16 and 17
are within the loop of the predicted stem-loop structure and are therefore tolerated in the structural prediction shown in (B). (B) The predicted secondary structure of
direct repeats and the associated Minimum Free Energy (MFE) estimated in (kcal/mol) shown underneath the structure. This structure is predicted to be involved in
the mechanism of pre-crRNA processing. (C) Type IV-A-variant conserved putative protospacer adjacent motifs (PAMs). The alignment of the regions containing
protospacers shows the conservation of putative PAM signature (AAG), position –3 to –1, adjacent to the end of the protospacers, using WebLogo. The analysis was
performed on all the detected (467 spacers) of the 31 CRISPR1 arrays analyzed, specifically, spacer matching 9% (42/467) to bacteriophages and 25.5% (119/467)
to plasmid sequences. Searches for other subtypes/variants were unsuccessful, likely due to the low number of spacer–protospacer matches (D) Conserved Type
IV-A-variant CRISPR leader. The WebLogo shows a highly conserved 65 bp occurring between the CRISPR-Cas loci an the CRISPR array among the sequences
investigated in this study.
TABLE 2 | RT-PCR data of the confirmed cas loci (cas7, dinG, and cas6) in the three clinical isolates.
Isolate Gene†
rpoB* cas7/csf2 dinG/csf4 cas6/csf5
K. pneumoniae-CR5 16.71 22.385 23.865 23.69
K. pneumoniae-CR5 RT-ve CTRL** 31.21 37.48 42.52 34.755
K. pneumoniae-53 16.595 24.2 25.305 25.325
K. pneumoniae-53 RT-ve CTRL** 32.65 37.74 34.37 33.61
K. pneumoniae-65 17.575 23.2 24.745 24.44
K. pneumoniae-65 RT-ve CTRL** 32.23 42.79 46 34.045
†Genes amplification data represent the average of two experiments at least. The cut-off cycle threshold (Ct) was 30 cycles. *rpoB housekeeping gene was used as the
internal positive control. **RT-ve CTRL represent no addition of the reverse transcriptase which was used as the negative control for residual DNA.
in Enterobacteriaceae with chromosomal Type I-E/I-E∗ CRISPR-
Cas (Kamruzzaman and Iredell, 2019), we could not identify
Type I-E/I-E∗ in all the isolate genomes that have Type IV-A3.
For example, K. pneumoniae-53, CP011314.1, HG918041.1,
JN420336.1, MF150122.1, CP014776.1, CP018339.1, CP026398.1,
CP020848.1, CP024507.1, CP026172.1, and CP025462.1 did not
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FIGURE 3 | Newly described Type IV-A3 CRISPR spacer polymorphism. The spacers map. Only spacers are represented by boxes, and no repeats are included.
Identical spacers are represented by the same number and color, while unique spacers are represented by white color and no number is associated with the box.
Self-targeting spacers are indicated by letter (S) and show 100% identity to host DNA, plasmid-targeting spacers are indicated by letter (P), phage targeting spacers
are indicated by letters (Ph), other Enterobacteriaceae targeting spacers (100% identity) are indicated by letter (O), cryptic spacers with similarity to other bacterial
DNA are indicated by letters (CO), and those with similarity to Eukaryotic DNA are indicated by letters (CE) that are positioned underneath the relevant spacer. CE
spacers showed at least 57% identity to eukaryotic DNA. CE spacers were confirmed by multiple sequences alignments. * KY913897.1 is the isolate that only has a
CRISPR array and a cas7 (csf2) (not a complete Type IV system) and therefore is not included in the total analysis in Figure 4.
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FIGURE 4 | Evolutionary relationships of Type IV-A3 CRISPR spacer. The phylogenetic tree illustrating the evolutionary relationships of Type IV-A3 CRISPR array
nucleotide sequences. Phylogenetic UPGMA tree was constructed using the MUSCLE algorithm of MEGA7. The evolutionary distances were computed using the
Maximum Likelihood method and Tamura-Nei model, bootstrap test (1000 replicates), and the rate variation among sites was modeled with a gamma distribution
(shape parameter = 2). The percentage of trees in which the associated taxa clustered together is shown next to the branches. The year and geographical origin of
the isolate are listed to the right of the branch ends.
have Type I-E/I-E∗ CRISPR-Cas systems. Thus, we assume there
is no conditional connection between the presence of Type IV-A3
and Type I-E/I-E∗ CRISPR-Cas systems in Enterobacteriaceae.
Type IV-A3 CRISPR system reported here is exclusively
located on IncH1B/IncFIB plasmids. We have also spotted
an imperfect spacer target in traN of an IncFIIK plasmid
in K. pneumoniae-53 which suggests this plasmid may
be able to evade plasmid mediated CRISPR interaction
within this strain (Jiang et al., 2013). Therefore, these
spacers are likely to be involved in plasmid competition;
protecting the resident Type IV-A CRISPR-Cas carrying
plasmid in Enterobacteriaceae as previously suggested
(Newire et al., 2019; Pinilla-Redondo et al., 2019).
Recently, some Type IV-A system variants that are
associated with P. aeruginosa were shown to target
invasive plasmids, which strengthens the involvement of
Type IV-A CRISPR-Cas systems in plasmid competition
(Crowley et al., 2019).
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Type IV CRISPR-Cas systems demonstrate a notable diversity
of molecular organization (Figure 1) and some appear to have
taken on roles in addition to adaptive cellular immunity (Faure
et al., 2019a). For example, some of the Type IV CRISPR–
Cas loci were previously predicted to encode bacterial toxins
that together with the Cas proteins of the Type IV systems
may contribute to plasmid stabilization (Faure et al., 2019b).
The Type IV-A3 system described here demonstrates a complex
evolutionary connection with MGEs in terms of parasitism
and immunity (Koonin and Makarova, 2017). The association
between this Type IV-A3 system and multiple MGEs, plus
the identification of partial cas loci genes with and without
the CRISPR array on other IncHI1B/IncFIB(Mar) plasmids
(Figure 1 and Supplementary Table S1), plus the identification
of similar arrays in different plasmids in the same host from
the same country (Figures 3, 4), indicates that dynamic, MGE
mediated movement and rearrangement of this CRISPR-Cas
Type IV-A system is ongoing. The similarity in the GC content
between this Type IV-A and the IncHI1B/IncFIB plasmids in
contrast with the higher chromosomal GC content supports the
observations that the system is exclusively plasmid associated,
both in this study and in others (Ravenhall et al., 2015).
Because reporting standard deviations from comparisons of
element-wide GC contents across different genomes could be
misleading, since the strains are closely related that statistical
observations are not independent, we have investigated the
GC skew in a reasonably sized sliding window (1000 bp)
across the length of the element (Type IV-A3 system and
plasmid DNA sequences) in a single genome (K. pneumoniae-
65), which also confirmed that the system is exclusively
plasmid associated. This demonstrates unique evolutionarily
juxtaposed connections between CRISPR-Cas and MGEs which
is worthy of further investigation. To our knowledge, this
is the first identification of a CRISPR-Cas system exclusively
associated with IncHI1B/IncFIB plasmids that demonstrates an
evolutionary association with MGEs and is likely to be involved
in plasmid competition.
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